{"filing":{"accession_number":"0000926617-26-000047","cik":"0000926617","ticker":"AWHL","company_name":"Aspira Women's Health Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"awhl-20260617x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000047/awhl-20260617x8k.htm"},"events":[{"id":12661,"run_id":11231,"accession_number":"0000926617-26-000047","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"Michael Buhle ceased serving as Chief Executive Officer on June 17, 2026. While the filing also discloses John Fraser's appointment as Interim CEO, the principal disclosed action centers on the CEO's departure. The departure is material as it affects the registrant's leadership and investor assessment of operational continuity, though the non-contentious nature and interim replacement arrangement somewhat mitigate the severity.","company_name":"Aspira Women's Health Inc.","ticker":"AWHL","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9569,"accession_number":"0000926617-26-000047","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Michael Buhle ceased serving as Chief Executive Officer on June 17, 2026. While the filing also discloses John Fraser's appointment as Interim CEO, the principal disclosed action centers on the CEO's departure. The departure is material as it affects the registrant's leadership and investor assessment of operational continuity, though the non-contentious nature and interim replacement arrangement somewhat mitigate the severity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:30:36.290738+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9569,"accession_number":"0000926617-26-000047","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Michael Buhle ceased serving as Chief Executive Officer on June 17, 2026. While the filing also discloses John Fraser's appointment as Interim CEO, the principal disclosed action centers on the CEO's departure. The departure is material as it affects the registrant's leadership and investor assessment of operational continuity, though the non-contentious nature and interim replacement arrangement somewhat mitigate the severity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:30:36.290738+00:00","company_name":"Aspira Women's Health Inc.","ticker":"AWHL","filing_date":"2026-06-22"}]}